Dr. Mok on Plasma Testing Approaches in Lung Cancer

Tony S.K. Mok, BMSc, MD, FRCPC
Published: Friday, Aug 09, 2013

Tony S.K. Mok, BMSc, MD, FRCPC, Professor, Department of Clinical Oncology, Chinese University of Hong Kong, Prince of Wales Hospital Hong Kong, China, discusses different plasma testing approaches for patients with lung cancer.

Mok says that a physician has the option to conduct a plasma test when the diagnosis is being made. By the time the lung cancer diagnosis is confirmed, a physician will have plasma testing results available. If the test is positive, treatment can begin, but if it is negative, a physician can subject the tumor for testing.

If good tissue cannot be obtained for testing, a physician can use plasma as a testing method but should be aware that sensitivity is only 76%.

Tony S.K. Mok, BMSc, MD, FRCPC, Professor, Department of Clinical Oncology, Chinese University of Hong Kong, Prince of Wales Hospital Hong Kong, China, discusses different plasma testing approaches for patients with lung cancer.

Mok says that a physician has the option to conduct a plasma test when the diagnosis is being made. By the time the lung cancer diagnosis is confirmed, a physician will have plasma testing results available. If the test is positive, treatment can begin, but if it is negative, a physician can subject the tumor for testing.

If good tissue cannot be obtained for testing, a physician can use plasma as a testing method but should be aware that sensitivity is only 76%.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Novel Therapeutic Options for Lung Neuroendocrine TumorsMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x